Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Defensin beta 109D is a member of the beta-defensin gene family found encoded in the human genome, but it is classified as a pseudogene and does not produce a functional protein product[4]. While other beta-defensins function as cationic antimicrobial peptides and play important roles in innate immune defense and immune modulation[1][2], DEFB109D does not share these activities due to its pseudogene annotation, and it is not considered a molecular target for drug discovery, disease modulation, or biomarker applications[4]. If you require information about active beta-defensin family members (such as DEFB1, DEFB2, DEFB3) which do display clear biological function and therapeutic relevance, please specify the full gene/protein designation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Defensin beta 109D pseudogene (DEFB109D).